Treatment for recurrent ovarian cancer - At first relapse

Journal of Oncology

Volumn , Issue , 2010, Pages

  Ushijima, Kimio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN;

ALOPECIA; AREA UNDER THE CURVE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY; LOW DRUG DOSE; MEDICAL DECISION MAKING; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PATIENT SELECTION; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77951672107     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/497429     Document Type: Review

References (42)

1. Herzog T. J., Recurrent ovarian cancer: how important is it to treat to disease progression? Clinical Cancer Research 2004 10 22 7439 7449
2. Rose P. G., Fusco N., Fluellen L., Rodriguez M., Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma Journal of Clinical Oncology 1998 16 4 1494 1497 (Pubitemid 28175771)
3. du Bois A., Lck H. J., Pfisterer J., Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancera dose-finding study by the Arbeitsgemeinschaft Gynkologische Onkologie (AGO) Ovarian Cancer Study Group Annals of Oncology 2001 12 8 1115 1120 (Pubitemid 32834492)
4. Power P., Stuart G., Oza A., Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study Gynecologic Oncology 2009 114 3 410 414
5. Ushijima K., Hirakawa T., Saitoh T., Phase II study of docetaxel and carboplatin in patients with recurrent epithelial ovarian cancer after first-line treatment with paclitaxel and/or platinum treatment Proceedings of the 10th IGCS Biennial Meeting October 2004 Edinburgh, UK. abstract no. #469
6. The ICON and AGO Collaborators, Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial The Lancet 2003 361 2099 2106
7. Gonzlez-Martn A. J., Calvo E., Bover I., Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espa ol de Investigacin en Cncer de Ovario) study Annals of Oncology 2005 16 5 749 755 (Pubitemid 40767095)
8. Pfisterer J., Plante M., Vergote I., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG Journal of Clinical Oncology 2006 24 29 4699 4707 (Pubitemid 46630933)
9. Alberts D. S., Liu P. Y., Wilczynski S. P., Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200) Gynecologic Oncology 2008 108 1 90 94
10. Pujiade-Lauraine E., Mahner S., Kaern J., A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Inter Group (GCIG) Proceedings of the ASCO Annual Meeting 2009. abstract no. #5509
11. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., Belinson J., Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecologic Oncology 2003 90 3 593 596
12. Garcia A. A., OMeara A., Bahador A., Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer Gynecologic Oncology 2004 93 2 493 498 (Pubitemid 38507624)
13. OMalley D. M., Azodi M., Makkenchery A., Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma Gynecologic Oncology 2005 98 2 242 248 (Pubitemid 41019112)
14. Mutch D. G., Orlando M., Goss T., Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer Journal of Clinical Oncology 2007 25 19 2811 2818 (Pubitemid 47123191)
15. Bookman M. A., Malmstrm H., Bolis G., Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel Journal of Clinical Oncology 1998 16 10 3345 3352 (Pubitemid 28481631)
16. Gadducci A., Fuso L., Cosio S., Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study International Journal of Gynecological Cancer 2009 19 3 367 374
17. Gadducci A., Sartori E., Maggino T., Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study International Journal of Gynecological Cancer 1997 7 6 445 450 (Pubitemid 28020705)
18. Hoskins P., Tu D., James K., Pater J., Koski B., Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups Gynecologic Oncology 1998 70 2 224 230 (Pubitemid 28430934)
19. Ferrandina G., Paris I., Ludovisi M., Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival Gynecologic Oncology 2005 98 2 267 273
20. Verhaar-Langereis M., Karakus A., Van Eijkeren M., Voest E., Witteveen E., Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer International Journal of Gynecological Cancer 2006 16 1 65 70
21. Chi D. S., McCaughty K., Diaz J. P., Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 2006 106 9 1933 1939
22. Markman M., Rothman R., Hakes T., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin Journal of Clinical Oncology 1991 9 3 389 393
23. Gore M. E., Fryatt I., Wiltshaw E., Dawson T., Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecologic Oncology 1990 36 2 207 211 (Pubitemid 20061287)
24. Ozols R. F., Recurrent ovarian cancer: evidence-based treatment Journal of Clinical Oncology 2002 20 5 1161 1163
25. Thigpen J. T., Blessing J. A., Ball H., Hummel S. J., Barrett R. J., Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study Journal of Clinical Oncology 1994 12 9 1748 1753
26. Colombo N., Gore M., Treatment of recurrent ovarian cancer relapsing 612 months post platinum-based chemotherapy Critical Reviews in Oncology/Hematology 2007 64 2 129 138
27. Spriggs D., Optimal sequencing in the treatment of recurrent ovarian cancer Gynecologic Oncology 2003 90 3, supplement S39 S44
28. Vasey P. A., Jayson G. C., Gordon A., Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherpy for ovarian carcinoma Journal of the National Cancer Institute 2004 96 22 1682 1691 (Pubitemid 39585637)
29. Ozols R. F., Treatment goals in ovarian cancer International Journal of Gynecological Cancer 2005 15 supplement 1 3 11
30. Muggia F. M., Hainsworth J. D., Jeffers S., Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation Journal of Clinical Oncology 1997 15 3 987 993 (Pubitemid 27106281)
31. Gordon A. N., Granai C. O., Rose P. G., Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer Journal of Clinical Oncology 2000 18 17 3093 3100
32. Rose P. G., Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer The Oncologist 2005 10 3 205 214 (Pubitemid 40463158)
33. Thigpen J. T., Aghajanian C. A., Alberts D. S., Role of pegylated liposomal doxorubicin in ovarian cancer Gynecologic Oncology 2005 96 1 10 18
34. Sehouli J., Review of gemcitabine-based combinations for platinum-resistant ovarian cancer International Journal of Gynecological Cancer 2005 15 supplement 1 23 30
35. Kudelka A. P., Tresukosol D., Edwards C. L., Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma Journal of Clinical Oncology 1996 14 5 1552 1557 (Pubitemid 26134213)
36. Rodriguez M., Rose P. G., Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer Gynecologic Oncology 2001 83 2 257 262
37. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J., Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer Gynecologic Oncology 2000 79 1 116 119
38. Gordon A. N., Fleagle J. T., Guthrie D., Parkin D. E., Gore M. E., Lacave A. J., Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan Journal of Clinical Oncology 2001 19 14 3312 3322
39. Tay E.-H., Grant P. T., Gebski V., Hacker N. F., Secondary cytoreductive surgery for recurrent epithelial ovarian cancer Obstetrics and Gynecology 2002 99 6 1008 1013
40. Eisenkop S. M., Friedman R. L., Spirtos N. M., The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma Cancer 2000 88 1 144 153
41. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., Genazzani A. R., Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer Gynecologic Oncology 2000 79 3 344 349
42. Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., Taketani Y., Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection British Journal of Cancer 2005 92 6 1026 1032